Novo Nordisk beat Q4 consensus on revenue and adjusted EPS, driven by 31% obesity-care growth, yet shares fell nearly 40% after a shocking FY2026 guidance cut. Gross margin compressed as D&A and ...

(Bloomberg) -- Novo Nordisk A/S’s next-generation obesity shot delivered less weight loss than Eli Lilly & Co.’s rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...

Novo Nordisk A/S’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete ...